US › Healthcare

Viatris Inc (VTRS)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$17.70+0.40%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$3.52B
Revenue YoY
+8.1%
Net profit
$176.4M
Profit YoY
+105.8%
EPS
$0.59
EPS estimate
$0.50
Net margin
5.0%

EPS came in at 0.59 against a street estimate of 0.50 — a beat of 18.0%.

Key statistics

Market cap
$20.45B
Forward P/E
7.1
P/B
1.40
Book value
$12.59
EPS (TTM)
$-0.30
Dividend yield
2.70%
52-week high
$18.07
52-week low
$8.41
50-day MA
$16.48
200-day MA
$13.95
Beta
0.90

Analyst view

Analysts rate Viatris Inc a hold (3 buy, 5 hold, 1 sell out of 9) with an average price target of $17.94.

Shareholding

Insiders
0.31%
Institutions
88.18%

Largest institutional holders

FundStake
BlackRock Inc7.24%
Davis Selected Advisers6.72%
Vanguard Capital Management, LLC6.42%
T. Rowe Price Associates, Inc.5.66%
Vanguard Portfolio Management, LLC4.63%
State Street Corp4.49%
Dimensional Fund Advisors, Inc.3.29%
Rubric Capital Management LP2.88%

Recent filings & reports

DocumentDate
Material agreement · Q3 20262026-07-01
Material agreement · Q2 20262026-06-18
Company announcement · Q2 20262026-06-15
Shareholder vote results · Q2 20262026-05-15
Quarterly report · Q1 20262026-05-07
Proxy statement · Q2 20262026-04-02
Annual report FY20252026-02-26
Quarterly report · Q3 20252025-11-06

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Viatris Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.